DOCSLIB.ORG

ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) in PATIENTS with REGIONAL ISCHEMIA and INFARCTION on MYOCARDIAL PERFUSION IMAGES Alireza Esfahane

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) in PATIENTS with REGIONAL ISCHEMIA and INFARCTION on MYOCARDIAL PERFUSION IMAGES Alireza Esfahane University of New Mexico UNM Digital Repository Biomedical Sciences ETDs Electronic Theses and Dissertations 7-1-2015 ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PATIENTS WITH REGIONAL ISCHEMIA AND INFARCTION ON MYOCARDIAL PERFUSION IMAGES Alireza Esfahane Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds Recommended Citation Esfahane, Alireza. "ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PATIENTS WITH REGIONAL ISCHEMIA AND INFARCTION ON MYOCARDIAL PERFUSION IMAGES." (2015). https://digitalrepository.unm.edu/biom_etds/95 This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. Alireza B. Esfahane Candidate Internal Medicine Department This thesis is approved, and it is acceptable in quality and form for publication: Approved by the Thesis Committee: Cameron Crandall, M.D., Ph.D., Chairperson Abass Alavi, M.D. Denece Kesler, M.D., MPH Herbert Davis, Ph.D. i ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PATIENTS WITH REGIONAL ISCHEMIA AND INFARCTION ON MYOCARDIAL PERFUSION IMAGES By ALIREZA B. ESFAHANE M.D., Tehran University of Medical Sciences, 1997 THESIS Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science -Biomedical Sciences The University of New Mexico Albuquerque, New Mexico July, 2015 ii DEDICATION This thesis is dedicated to my family iii ACKNOWLEDGEMENTS Foremost, I would like to express my sincere gratitude to my mentor Dr. Alavi for helping me through this research with the continuous support of my study, for his patience, motivation, enthusiasm, and immense knowledge. His guidance helped me throughout the research and writing of this thesis. I could not have had a better advisor and mentor for my master study. In addition to my mentor, I would like to thank the rest of my advisory committee: Dr. Crandall, Dr. Davis and Dr. Kesler, for their encouragement, insightful comments, and hard questions. My sincere thanks also go to my prior program director, Dr. Hankins for training me as a nuclear medicine physician. He was a wonderful teacher to me and helped me to collect the data for this study. I would like to express my gratitude to all of the Department faculty members for their help and support. I would also like to thank my family for the support that they provided me throughout my entire life. iv ASSOCIATION BETWEEN LEFT VENTRICULAR EJECTION FRACTION (LVEF) IN PATIENTS WITH REGIONAL ISCHEMIA AND INFARCTION ON MYOCARDIAL PERFUSION IMAGES1 by Alireza B. Esfahane M.D., Tehran University of Medical Sciences, 1997 Master of Science -Biomedical Sciences, University of New Mexico, 2015 ABSTRACT OBJECTIVES: We used gated single-photon emission computed tomography Technetium (99mTc) tetrofosmin (SPECT Myoview), myocardial perfusion imaging (MPI) to (i) determine whether the location of myocardial infarction and Ischemia affect left ventricular function, and (ii) associated changes between post-stress (SEF) and rest ejection fraction (REF) with segmental perfusion abnormalities. METHODS: Five hundred ninety-eight patients underwent a rest- stress or stress– rest gated SPECT Myoview. A Quantitative Gated SPECT (QGS) software program was used to calculate the left ventricular ejection fraction at rest and stress. The left ventricle was divided into thirteen segments. The perfusion abnormalities on each segment were visually assessed. The patients’ scans were divided into 4 groups with ischemia, infarction, artifact and no findings on scans. Associations between the segments and SEF, REF were studied. 1 Alireza B. Esfahane, University of New Mexico; Cameron Crandall, University of New Mexico; Herbert Davis, University of New Mexico; Denece Kesler, University of New Mexico, Jordan H. Hankins, University of Nebraska Medical Center; Abass Alavi, University of Pennsylvania. v RESULTS: Patients with artifact showed no statistically significant association with decrease in either REF or SEF at any segments. Multiple segments among the patients with infarction showed association with REF or SEF including; anterior apical segment (REF p 0.039, Coeff – 10.07) apex (REF p 0.000, Coeff – 4.83), mid septal segment (SEF p 0.011, Coeff -18.61), anterior apical segment (SEF p 0.032, Coeff -9.93), apical lateral segment (SEF p 0.035, Coeff – 11.45) and apex (SEF p0.000, Coeff -5.48). The patients with ischemia showed only association with SEF on the mid septal segment (SEF p 0.038, Coeff -10.50). CONCLUSION: The segmental perfusion abnormality showed significant association with REF and SEF mostly after myocardial infarction. In this group, 4 out of 13 segments showed significant association with decreasing LVEF. Only the anterior apical segment and apex showed an association with REF while the anterior and lateral apical segments, mid septal and apex showed significant association with decreasing SEF after infarction. No significant association between any segments involved in artifact and LVEF were identified but ischemia showed association only with SEF if mid septal segment was involved. The global LVEF is the most affected by the mid septal segment in myocardial infarction. The overall results suggested that some of the segments of the infarction are more associated with decreasing LVEF compared to the other segments of the myocardium. Keywords: gated SPECT Myoview, left ventricular function, myocardial infarction, perfusion abnormalities vi TABLE OF CONTENTS LIST OF FIGURES ............................................................................................................. viii LIST OF TABLES ............................................................................................................... ix INTRODUCTION ............................................................................................................... 1 METHODS ...................................................................................................................... 11 Study Population ......................................................................................................... 11 Assessment and Data Acquisition ............................................................................... 13 Data Reconstruction and Image Analysis ................................................................... 14 Study Models .............................................................................................................. 15 Statistical Analysis ....................................................................................................... 16 RESULTS......................................................................................................................... 18 DISCUSSION ................................................................................................................... 29 CONCLUSION ................................................................................................................. 38 REFERENCES .................................................................................................................. 39 APPENDIX A: DATA TABLES AND FIGURES ...................................................................... 49 Tables ......................................................................................................................... 49 Figures ......................................................................................................................... 55 vii LIST OF FIGURES Figure 1: Tc-99m is used in myocardial perfusion imaging (i.e., comparing a 'rest' and 'stress' image to identify ischemia/infarction), avid infarct imaging (to detect damaged myocardial tissue post-MI) and cardiac function studies (to determine how well the heart is pumping via LVEF). ........................................................................................... 3 Figure 2: 2 D image of MPI Left Ventricle, which is divided into 13 segments. ..................... 13 Figure 3: Association of Rest Ejection Fraction (REF, green arrows) and Stress Ejection Fraction (SEF, blue arrows) with segmental infarction. Coefficient (C) and p values are shown. ................................................................................................................... 32 Figure 4: Association of segmental infarction with Rest Ejection Fraction (REF, green arrows) and Stress Ejection Fraction (SEF, blue arrows).......................................................... 35 Figure A-1: Distribution of Rest Ejection Fraction among all patients. .................................. 55 Figure A-2: Distribution of Stress Ejection Fraction among all patients. ................................ 56 viii LIST OF TABLES Table 1: The table shows the frequency of involvement of each of the thirteen myocardial segments in ischemia, infarction and artifact. ........................................................... 19 Table 2: Rest Ejection Fraction (REF) shown among four groups of the patients. ................. 20 Table 3: Distribution of Stress Ejection Fraction (SEF) among 4 groups of patients .............. 20 Table 4: Association between Rest Ejection Fraction (REF) and 13 cardiac segments among patients with ischemia, infarction or artifact are shown. .......................................... 23 Table 5: Association between
Load more

Recommended publications
  • List Item Withdrawal Assessment Report for Folcepri
    20 March 2014 EMA/CHMP/219148/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Folcepri International non-proprietary name: etarfolatide Procedure No.: EMEA/H/C/002570/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. This AR reflects the CHMP opinion on 20 March 2014, which originally recommended to approve this medicine. The recommendation was conditional to the results of the on-going confirmatory study EC-FV-06. Before the marketing authorisation was granted by the EC, the results of this study became available and did not support the initial recommendation. Subsequently, the company decided to withdraw the application and not to pursue any longer the authorisation for marketing this product. The current report does not include the latest results of this study as the withdrawal of the application did not allow for the CHMP to revise its opinion in light of the new data. For further information please refer to the Q&A which followed the company’s withdrawal of the application. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ...............................................................................
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Radiotracers for SPECT Imaging: Current Scenario and Future Prospects
    Radiochim. Acta 100, 95–107 (2012) / DOI 10.1524/ract.2011.1891 © by Oldenbourg Wissenschaftsverlag, München Radiotracers for SPECT imaging: current scenario and future prospects By S. Adak1,∗, R. Bhalla2, K. K. Vijaya Raj1, S. Mandal1, R. Pickett2 andS.K.Luthra2 1 GE Healthcare Medical Diagnostics, John F Welch Technology Center, Bangalore, India 560066 2 GE Healthcare Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, HP7 9LL, UK (Received October 4, 2010; accepted in final form July 18, 2011) Nuclear medicine / 99m-Technetium / 123-Iodine / ton emission computed tomography (SPECT or less com- Oncological imaging / Neurological imaging / monly known as SPET) and positron emission tomogra- Cardiovascular imaging phy (PET). Both techniques use radiolabeled molecules to probe molecular processes that can be visualized, quanti- fied and tracked over time, thus allowing the discrimination Summary. Single photon emission computed tomography of healthy from diseased tissue with a high degree of con- (SPECT) has been the cornerstone of nuclear medicine and today fidence. The imaging agents use target-specific biological it is widely used to detect molecular changes in cardiovascular, processes associated with the disease being assessed both at neurological and oncological diseases. While SPECT has been the cellular and subcellular levels within living organisms. available since the 1980s, advances in instrumentation hardware, The impact of molecular imaging has been on greater under- software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper. standing of integrative biology, earlier detection and charac- The biggest change in the last decade has been the fusion terization of disease, and evaluation of treatment in human of CT with SPECT, which has improved attenuation correction subjects [1–3].
    [Show full text]
  • Non-Coding Rnas in the Cardiac Action Potential and Their Impact on Arrhythmogenic Cardiac Diseases
    Review Non-Coding RNAs in the Cardiac Action Potential and Their Impact on Arrhythmogenic Cardiac Diseases Estefania Lozano-Velasco 1,2 , Amelia Aranega 1,2 and Diego Franco 1,2,* 1 Cardiovascular Development Group, Department of Experimental Biology, University of Jaén, 23071 Jaén, Spain; [email protected] (E.L.-V.); [email protected] (A.A.) 2 Fundación Medina, 18016 Granada, Spain * Correspondence: [email protected] Abstract: Cardiac arrhythmias are prevalent among humans across all age ranges, affecting millions of people worldwide. While cardiac arrhythmias vary widely in their clinical presentation, they possess shared complex electrophysiologic properties at cellular level that have not been fully studied. Over the last decade, our current understanding of the functional roles of non-coding RNAs have progressively increased. microRNAs represent the most studied type of small ncRNAs and it has been demonstrated that miRNAs play essential roles in multiple biological contexts, including normal development and diseases. In this review, we provide a comprehensive analysis of the functional contribution of non-coding RNAs, primarily microRNAs, to the normal configuration of the cardiac action potential, as well as their association to distinct types of arrhythmogenic cardiac diseases. Keywords: cardiac arrhythmia; microRNAs; lncRNAs; cardiac action potential Citation: Lozano-Velasco, E.; Aranega, A.; Franco, D. Non-Coding RNAs in the Cardiac Action Potential 1. The Electrical Components of the Adult Heart and Their Impact on Arrhythmogenic The adult heart is a four-chambered organ that propels oxygenated blood to the entire Cardiac Diseases. Hearts 2021, 2, body. It is composed of atrial and ventricular chambers, each of them with distinct left and 307–330.
    [Show full text]
  • Development and Evaluation of Radiotracers for Tumor Imaging Via
    Development and Evaluation of Radiotracers for Tumor Imaging via Positron Emission Tomography Dissertation zur Erlangung des Grades eines “Doktor rerum naturalium (Dr. rer. nat.)“ im Promotionsfach Chemie Am Fachbereich Chemie, Pharmazie und Geowissenschaften der Johannes Gutenberg-Universität Mainz Kathrin Kettenbach geboren in Mainz Mainz, im Februar 2017 Dekan: Erster Berichterstatter: Zweiter Berichterstatter: Tag der mündlichen Prüfung: 06.06.2017 Die vorliegende Arbeit wurde in der Zeit von 2013 bis 2017 am Institut für Kernchemie der Johannes Gutenberg-Universität Mainz angefertigt. „I hereby declare that I wrote the dissertation submitted without any unauthorized external assistance and used only sources acknowledged in this work. All textual passages which are appropriated verbatim or paraphrased from published and unpublished texts as well as information obtained from oral sources are duly indicated and listed in accordance with bibliographical rules. In carrying out this research, I complied with the rules of standard scientific practice as formulated in the statutes of Johannes Gutenberg-University Mainz to insure standard scientific practice.” Mainz, Februar 2017 Abstract Positron emission tomography (PET) enables the non-invasive imaging of metabolical processes in the human body. Thus, the use of radiolabeled cancer-specific targeting vectors can facilitate early diagnosis of tumors. A robust and reliable attachment of the radionuclide to the bioactive compound without major influences on its pharmacokinetic behavior is mandatory for routine PET imaging. In the herein presented work two different 18F-prosthetic groups for the radiolabeling of biomolecule-azides via click chemistry were evaluated. First, a strained prosthetic group based on (aza)dibenzocyclooctyne (DBCO) was developed to enable copper-free strain-promoted alkyne-azide cycloadditions (SPAAC) with biomolecule-azides.
    [Show full text]
  • Tauvid Integrated Review Document
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212123Orig1s000 INTEGRATED REVIEW Executive Summary Interdisciplinary Assessment Appendices NDA212123 Tauvid (flortaucipir F 18 injection) Integrated Review Table 1. Administrative Application Information Category Application Information Application type NDA Application number{s) 212123 Priority or standard Ptiority Submit date{s) 9/30/2019 Received date(s) 9/30/2019 PDUFA goal date 5/29/2020 Division/office Division oflmaging and Radiation Medicine (DIRM) Review completion date 5/27/2020 Established name Flo1taucipir F 18 (Proposed) trade name Tauvid Pharmacologic class Radioactive diagnostic agent (for PET imaging) Code name F18-AV-1451 , F18-T807, LSN3182568 Applicant Avid Radiopha1maceuticals Inc Dose form/formulation(s) Injection Dosing regimen 370 MBq (10 mCi), administered as a bolus intravenous injection Applicant proposed For positron emission tomography (PET) imaging ofthe brain to indication{s)/population{s) estimate the density and disttibution of ag~gated tau 4 nemofibrillary tangles (NFTs) !b>T m adult oatients who are bein~evaluat~d for AD (b)(4__<l>H_ •l Proposed SNOMED indication Regulatory action Approval Approved Tauvid is indicated for use with PET imaging of the brain to indication{s)/population{s) estimate the density and disttibution of aggregated tau NFTs in {if applicable) adult patients with cognitive impaiiment who are being evaluated for AD. Limitations ofUse: Tauvid is not indicated for use in the evaluation ofpatients for chronic traumatic encephalopathy (CTE) Approved SNOMED 386806002 Ihnpaired cognition (fmdiI1g) indication Integrated Review Template, version date 2019/09/25 Reference ID: 4615642 NDA212123 Tauvid (flortaucipir F 18 injection) Table of Contents Table ofTables ....................................................................................................................v Table ofFigures ...............................................................................................................
    [Show full text]
  • Comparison of Gated Myocardial Perfusion SPECT, Echocardiography and Equilibrium Radionuclide Ventriculography in the Evaluation of Left Ventricle Contractility
    Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2014;42(4):349-357 doi: 10.5543/tkda.2014.74150 349 Comparison of gated myocardial perfusion SPECT, echocardiography and equilibrium radionuclide ventriculography in the evaluation of left ventricle contractility Sol ventrikül kontraktil fonksiyonlarının değerlendirilmesinde equilibrium radyonüklid ventrikülografi, ekokardiyografi ve miyokart perfüzyon gated SPECT görüntülemenin karşılaştırılması Filiz Hatipoğlu, M.D., Zeynep Burak, M.D.,# Özgür Ömür, M.D.# Department of Nuclear Medicine, Afyon Kocatepe University Faculty of Medicine, Afyonkarahisar; #Department of Nuclear Medicine, Ege University Faculty of Medicine, Izmir ABSTRACT ÖZET Objectives: In this study, we investigated the reliability of Amaç: Çalışmamızda, sol ventrikül (SV) fonksiyonlarının gated myocardial perfusion single-photon emission comput- değerlendirilmesinde ‘miyokart perfüzyon gated SPECT’ erized tomography (GSPECT) for the evaluation of left ven- (GSPECT) yönteminin güvenilirliği araştırıldı, GSPECT ile tricle (LV) function. We compared left ventricle ejection frac- hesaplanan sol ventrikül ejeksiyon fraksiyonu (SVEF) orta- tion (LVEF) calculated with GSPECT with the values derived laması planar ‘equilibrium gated radyonüklid ventrikülografi’ from planar equilibrium-gated radionuclide ventriculography (ERVG) ve ekokardiyografi (EKO) ile elde edilen değerlerle (ERVG) and echocardiography (ECHO). karşılaştırıldı. Study design: Forty-eight patients with suspected coronary Çalışma planı: Koroner arter hastalığı (KAH) şüphesi
    [Show full text]
  • Clinical Characteristics and Prognosis Of
    Lyu et al. BMC Cardiovascular Disorders (2019) 19:209 https://doi.org/10.1186/s12872-019-1177-1 RESEARCH ARTICLE Open Access Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China Lyu Siqi, Yu Litian* , Tan Huiqiong, Liu Shaoshuai, Liu Xiaoning, Guo Xiao and Zhu Jun Abstract Background: Heart failure (HF) with mid-range ejection fraction (EF) (HFmrEF) has attracted increasing attention in recent years. However, the understanding of HFmrEF remains limited, especially among Asian patients. Therefore, analysis of a Chinese HF registry was undertaken to explore the clinical characteristics and prognosis of HFmrEF. Methods: A total of 755 HF patients from a multi-centre registry were classified into three groups based on EF measured by echocardiogram at recruitment: HF with reduced EF (HFrEF) (n = 211), HFmrEF (n = 201), and HF with preserved EF (HFpEF) (n = 343). Clinical data were carefully collected and analyzed at baseline. The primary endpoint was all-cause mortality and cardiovascular mortality while the secondary endpoints included hospitalization due to HF and major adverse cardiac events (MACE) during 1-year follow-up. Cox regression and Logistic regression were performed to identify the association between the three EF strata and 1-year outcomes. Results: The prevalence of HFmrEF was 26.6% in the observed HF patients. Most of the clinical characteristics of HFmrEF were intermediate between HFrEF and HFpEF. But a significantly higher ratio of prior myocardial infarction (p = 0.002), ischemic heart disease etiology (p = 0.004), antiplatelet drug use (p = 0.009), angioplasty or stent implantation (p = 0.003) were observed in patients with HFmrEF patients than those with HFpEF and HFrEF.
    [Show full text]
  • The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
    Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction..............................................
    [Show full text]
  • Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 As Novel Radiotracers for Imaging Aggregated Tau in AD
    Journal of Nuclear Medicine, published on September 28, 2017 as doi:10.2967/jnumed.117.196741 Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in Alzheimer’s Disease with Positron Emission Tomography Michael Honer1, Luca Gobbi1, Henner Knust1, Hiroto Kuwabara2,3, Dieter Muri1, Matthias Koerner1, Heather Valentine2,3, Robert F. Dannals2, Dean F. Wong2,3,4,5,6, Edilio Borroni1 1Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland 2Russell H. Morgan Department of Radiology, Division of Nuclear Medicine – PET Center, The Johns Hopkins University School of Medicine, Baltimore 3Section of High Resolution Brain PET, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore 4Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore 5Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore 6Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore Corresponding author: Dr. Michael Honer Pharma Research and Early Development (pRED) Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel, Switzerland E-mail: [email protected] Running foot line: PET imaging of tau Abstract Tau aggregates and amyloid-beta (Aβ) plaques are key histopathological features in Alzheimer‘s disease (AD) and are considered as targets for therapeutic intervention as well as biomarkers for diagnostic in vivo imaging agents. This study describes the preclinical in vitro and in vivo characterization of the 3 novel compounds RO6958948, RO6931643 and RO6924963 that bind specifically to tau aggregates and have the potential to become positron emission tomography (PET) tracers for future human use.
    [Show full text]
  • Radiopharmaceuticals in Neurological and Psychiatric Disorders
    International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015 ): PET-CT in the era of multimodality imaging and image-guided therapy October, 05-09, 2015, Vienna Radiopharmaceuticals in Neurological and Psychiatric Disorders Emilia Janevik Faculty of Medical Sciences Goce Delcev – Stip, Republic of Macedonia Everything that healthcare providers do has a real, meaningful impact on human life Nuclear medicine is the only imaging modality that depend of the injected radiopharmaceutical Every radiopharmaceutical that is administrated holds far more than just a radionuclide Radiopharmaceuticals want it to deliver confidence, efficiency and a higher standard of excellence. And above all, renewed hope for each patient’s future Radiopharmaceuticals for planar imaging, (SPECT), (PET), PET-CT or SPECT-CT fusion imaging PET-MRI is currently being developed for clinical application Understanding the utilization of radiopharmaceuticals for neurological and psychiatric disorders First contact…Projects related to International Atomic Energy Agency - IAEA: 1.(technical cooperation) 1995-1997 Preparation and QC od Technetium 99m Radiopharmaceuticals 99mTc - HMPAO DIAGNOSTIC APPLICATION OF SPECT RADIOPHARMACEUTICALS IN NEUROLOGY AND PSYCHIATRY The principal application areas for brain imaging include: - evaluation of brain death - brain imaging to assess the absence of cerebral blood flow - epilepsy - cerebrovascular disease - neuronal function - cerebrospinal fluid (CSF) dynamics - brain tumours Primarily technetium agents, including - nondiffusible tracers 99mTc-pertechnetate, 99mTc pentetate (Tc- DTPA) and 99mTc-gluceptate (Tc-GH) - diffusible tracers 99mTc-exametazime, hexamethylpropyleneamine oxime - (Tc-HMPAO) and 99mTc-bicisate, ethylcysteinate dimer (Tc-ECD) - Evaluation of brain death - brain imaging to assess the absence of cerebral blood flow Cerebral delivery of radiotracer Major arteries that distribute Major veins that drain blood to the brain after i.v.
    [Show full text]
  • Calcium-Activated Ion Currents in Heart Failure and Ischemia: Point Counter Point
    Open Access Full Text Article Journal of Cardiovascular Disorders A Austin Publishing Group Review Article Calcium-activated Ion Currents in Heart Failure and Ischemia: Point Counter Point William T Clusin* Division of Cardiology, Stanford University School of Abstract Medicine, USA A fundamental principle of cellular electrophysiology is that certain ionic *Corresponding author: William T Clusin, Division currents are activated (i.e. controlled) by the rise in and fall of cytosolic free of Cardiology, Stanford University School of Medicine, calcium at the inner surface of the cell membrane during action potentials and Stanford, CA, 94305, USA, Email: [email protected] the intervals between them. Knowledge about calcium-activated currents has developed in parallel with, and has been incorporated into emerging ideas Received: August 14, 2014; Accepted: September 17, about the mechanisms of cardiac arrhythmias and sudden death in patients with 2014; Published: September 19, 2014 heart disease. Among the earliest discoveries in this field was the recognition that calcium- activated inward current through the sodium calcium exchanger can lead to early or late after-depolarization’s (EAD’s and DAD’s) that trigger premature beats. More recently it has been found that calcium activated outward currents are more important in the heart than initially recognized because a group of calcium activated potassium channels known as SK channels is up-regulated in the ventricles during heart failure. Finally the idea that action potential shortening, which accompanies acute myocardial infarction, is a consequence of impaired calcium sequestration during ischemia, leading to increased outward potassium current, is supported by very recent research. The manner in which these different calcium activated ion currents in the heart regulate membrane potential and can cause – or in some cases prevent – arrhythmias is reconsidered in light of new evidence.
    [Show full text]